MedTrace Logo

Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent

NCT01233453 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2700

Last updated 2014-01-30

No results posted yet for this study

Summary

This is a prospective, randomized, multi center study. Approximately 2700 patients will be entered in the study and will be randomized on a 2:1 basis. Patients who meet the eligibility criteria will be randomized to the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent versus the Biolimus A9 eluting NOBORI® stent. Patients will be followed for 5 years.

Conditions

Interventions

DEVICE

the everolimus eluting ® stent

stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent

DEVICE

the Biolimus A9 eluting NOBORI® stent

stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent

Sponsors & Collaborators

  • Maasstad Hospital

    lead OTHER

Principal Investigators

  • Pieter C Smits, MD, PHD · Maasstad Ziekenhuis

  • A Serra, MD · Hospital del Mar

  • A J van Boven, MD, PHD · Medisch Centrum Leeuwarden

  • J J Goy, MD · Hopital Cantonal de Fribourg

  • V Voudris, MD · Onassis Heart Centre, Athens

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-05-31
Completion
2015-12-31

Countries

  • Greece
  • Netherlands
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233453 on ClinicalTrials.gov